Exosomal PD-L1: an effective liquid biopsy target to predict immunotherapy response

• 来源期刊: 国家科学评论（英文版）
• 年，卷（期）: 2019,（6）
• 页码范围: 1103-1104
• 页数: 2页
• 语种: 英文
• DOI: 10.1093/nsr/nwy154

摘要

Up-regulation of programmed death-ligand 1 (PD-L1) may allow cancer cells to evade the host immune system by recognizing the immune checkpoint programmed death-1 (PD-1) on T cells to promote self-tolerance by suppressing T-cell inflammatory activity [1].Blocking the interaction between PD-L1 and PD-1 has positive anti-tumor effects [2].Recently,several antibodies targeting the PD-L1/PD-1 pathway have been approved by the administration for the treatment of various tumors.However,only a minority of patients respond to the therapies [3].Therefore,a deeper insight into the mechanisms of the immune evasion is urgent to improve the effìcacy of these treatments.